Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
Rhea-AI Summary
Karyopharm (Nasdaq: KPTI) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will host a conference call and live audio webcast at 8:00 a.m. ET to discuss results and company updates.
Dial-in numbers are provided for domestic and international callers, and accompanying slides plus an archived webcast will be available on the company’s Investor "Events & Presentations" webpage about two hours after the call.
Positive
- None.
Negative
- None.
News Market Reaction – KPTI
In the Feb 5 session, KPTI declined 3.33%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Inducement RSU grants | Neutral | -3.2% | Reported 1,799 RSUs granted to new hires under inducement plan. |
| Jan 12 | Prelim 2025 revenue | Positive | -5.6% | Preliminary 2025 revenue ≈ $145M and key 2026 Phase 3 data objectives. |
| Jan 02 | Inducement RSU grants | Neutral | +2.9% | Two new hires received 1,533 RSUs under 2022 Inducement Plan. |
| Dec 08 | Investor event | Neutral | +2.4% | Announced virtual fireside chat participation in Baird’s Biotech Discovery Series. |
| Dec 01 | Inducement equity awards | Neutral | -6.8% | Issued options on 2,800 shares and 15,791 RSUs to new employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Routine corporate updates and inducement grant filings have generally seen modest, mixed reactions, while the positive preliminary 2025 revenue and Phase 3 outlook on Jan 12, 2026 coincided with a notably negative price move.
Over the past few months, Karyopharm’s news flow has centered on inducement equity grants, investor outreach, and 2025 performance visibility. On Dec 1, 2025 and multiple later dates, the company reported stock option and RSU inducement awards to new hires, with varied share price reactions. On Jan 12, 2026, Karyopharm released preliminary 2025 revenue of about $145M and highlighted key 2026 Phase 3 readouts, yet shares fell. Today’s announcement simply schedules the formal Q4 and full‑year 2025 earnings release and conference call on Feb 12, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
-- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET --
To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-12-2026-302679676.html
SOURCE Karyopharm Therapeutics Inc.